Tag: Septal
Mavacamten Demonstrated Significant Reduction in Need for Septal Reduction Thera… –...
Mavacamten is a first-in-class, investigational cardiac myosin inhibitor being developed by Bristol Myers Squibb
Study met all primary and secondary endpoints and patients receiving...